RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
HitGen of Chengdu will collaborate with Almirall. a Barcelona dermatology company, to identify novel small molecule leads for targets of interest. HitGen will search its DNA-encoded library technology platform, which is currently estimated to contain 400 billion leads, to discover, synthesize and screen the leads. Almirall asked HitGen to discover leads for new targets associated with atopic dermatitis. HitGen will receive upfront payments, and be eligible for milestone payments from Almirall, though specific financial details were not disclosed.
Source: China Biotoday
